If you were hoping to get the same omepazole pill for the same price, you may not have luck.
The drugmaker has announced it is discontinuing its popular capsule-sized omepizole pills in a new version due to a safety issue with aluminum in the manufacturing process.
The new capsules, which contain less than 1 milligram of aluminum, were only sold in a single-dose format for the past two years.
The company says the change will allow it to continue to offer the drug at a lower price, which could have cost it as much as $200 million.
The new capsules are also less likely to cause adverse side effects, according to the drugmaker.
The changes will be rolled out nationwide in early February, and then rolled out to all patients in late March.
The problem with aluminum is the fact that it is a common metal found in many plastics, including those used to make plastics and rubber, according the drugmakers website.
That means that when a patient swallows the pills, the metal can seep into the bloodstream.
The drugmaker says it has addressed the issue with the new capsule-size omepiazole, which will be manufactured with a process that removes aluminum.
It will not be sold in any larger-size capsules.
The company says that the changes are needed because it has a higher than average need for a longer-acting form of the drug, which can be needed in the event of a stroke or other potentially fatal complication.
The American Heart Association says that because the new capsules will have less aluminum than the capsules sold previously, they should be more effective in preventing stroke.
The association has said it will continue to monitor the drug for potential adverse effects.
The FDA has approved omepzole for the treatment of severe asthma, but not all doctors are comfortable using it in patients with other chronic conditions.
The agency said it is also concerned about the possibility of a higher rate of serious side effects with the capsule-only version of the pill, according a press release from the agency.
If those side effects persist, it could lead to the agency considering a change in its prescribing guidelines.
The Associated Press contributed to this report.